Poor hospitalization outcomes in patients undergoing allogeneic hematopoietic stem cell transplant with hospital acquired influenza infection

Authors

Mohammad Ammad Ud Din, Department of Hematology/Oncology, H. Lee Moffitt Cancer and Research Institute, Tampa, Florida, USA.
Ali Jaan, Rochester Regional HealthFollow
Moazzam Shahzad, Department of Hematology/Oncology, H. Lee Moffitt Cancer and Research Institute, Tampa, Florida, USA.
Hania Liaqat, Rochester Regional HealthFollow
Joseph McGuirk, Division of Hematologic Malignancies and Cellular Therapeutics, Medical Center, Kansas University, Kansas City, Kansas, USA.
Muhammad Umair Mushtaq, Division of Hematologic Malignancies and Cellular Therapeutics, Medical Center, Kansas University, Kansas City, Kansas, USA.

Department

Internal Medicine

Document Type

Article

Publication Title

Transplant Infectious Disease

Abstract

INTRODUCTION: Although hospital-acquired influenza infection (HAII) is a known complication among immunocompromised patients, the data in the setting of hospitalization for allogeneic hematopoietic stem cell transplant (allo-HSCT) are scarce.

METHODS: A retrospective study using the National Inpatient sample database was done to determine the impact of HAII on hospitalization outcomes among patients admitted for allo-HSCT.

RESULTS: The data for 77 103 allo-HSCT weighted hospitalizations were collected between 2002 and 2019. Among these, only 314 (0.4%) allo-HSCT cases were billed for HAII. Patients with influenza were more likely to have comorbid conditions like chronic obstructive lung disease, diabetes mellitus, hypertension, and myocardial infarction. Multivariate logistic regression revealed that patients with influenza had a higher risk of all-cause mortality: (odds ratio = 4.87, 95% confidence interval: 3.63-6.54; p < .01). Patients with influenza also had statistically higher odds of developing acute kidney injury, septic shock, and respiratory failure requiring mechanical ventilation. They also had a significantly longer length of stay (34 days versus 26 days) and adjusted cost for hospitalization ($195 345 versus $121 967).

CONCLUSION: Our large analysis of real-world data reveals that patients undergoing allo-HSCT that develop HAII are at substantially higher risk of inpatient complications and death.

First Page

e14066

DOI

10.1111/tid.14066

Volume

25

Issue

3

Publication Date

6-1-2023

PubMed ID

37129229

Recommended Citation

Ammad Ud Din, M., Jaan, A., Shahzad, M., Liaqat, H., McGuirk, J., & Mushtaq, M. U. (2023). Poor hospitalization outcomes in patients undergoing allogeneic hematopoietic stem cell transplant with hospital acquired influenza infection. Transplant Infectious Disease, 25 (3), e14066. https://doi.org/10.1111/tid.14066